Biome Australia Ltd

Biome Australia Ltd

AASX:BIO
0.38
AUD
+0.02
(+4.11%)
-0.01EPS
124.75MMarket Cap
Feb 23Next Earn
Biome Australia Ltd
ASX:BIO
(Australian Securities Exchange)

Recent

price

0.38

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
AUD
- -
0.02
0.04
0.06
- -
Revenue per Share
- -
-0.03
-0.02
-0.01
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
0.05
0.03
0.02
0.01
- -
Book Value per Share
0.05
0.03
0.02
0.01
- -
Tangible Book Value per Share
200
176
201
208
218
Basic Weighted Avg Shares
- -
4
7
13
- -
Sales/Revenue/Turnover
- -
-116.06
-46.36
-14.87
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
-5
-3
-2
- -
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-110.4
-42.55
-12.84
- -
Profit Margin (%)
10
8
7
3
- -
Working Capital
- -
- -
1
- -
- -
LT Debt
10
7
4
3
- -
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-54.39
-60.89
-51.47
- -
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
7
2024
- -
- -
13
2025
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.02
2024
- -
- -
-0.01
2025
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Business
Biome Australia Limited is a biotechnology company primarily engaged in the research, development, and commercialization of natural product-based pharmaceutical and cosmetic solutions. The company's core product portfolio includes the discovery and development of innovative botanical extracts and bioactive compounds for use in drug development, nutraceuticals, and cosmeceuticals. Biome Australia's offerings encompass natural health products, skin care formulations, and proprietary botanical ingredients designed to address a range of therapeutic and wellness applications. The company operates predominantly in Australia with a focus on leveraging Australia's unique biodiversity for commercial product development. Founded in 2001 and headquartered in Melbourne, Australia, Biome Australia has expanded its operational footprint through strategic partnerships and collaborative research alliances in the health and wellness sectors. In the last 1-2 years, the company has notably advanced its pipeline by launching new natural ingredient formulations and entering key partnerships to enhance its product innovation and market reach. These developments include alliances with pharmaceutical and cosmetic industry players to co-develop and license new botanical-based actives. Biome Australia has also bolstered its commercial capabilities to accelerate product launches and scale production. The company mainly serves pharmaceutical, cosmetic, and wellness markets, targeting customers seeking natural and scientifically validated product ingredients. It operates research and development laboratories and has established a network for clinical testing and regulatory compliance to support product claims. Biome Australia Limited is publicly traded on the Australian Securities Exchange under the ticker BIO.AX and continues to invest in proprietary technologies aimed at sustainable and effective natural health solutions. In sum, Biome Australia Limited is a biotechnology company focused on natural product discovery and development for pharmaceutical and cosmetic use, with a strong presence in Australia and recently expanded partnerships and product offerings designed to enhance its market presence and innovation pipeline.